Form 8-K - Current report:
SEC Accession No. 0001213900-24-082225
Filing Date
2024-09-26
Accepted
2024-09-26 16:00:19
Documents
15
Period of Report
2024-09-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0215822-8k_inmune.htm   iXBRL 8-K 25213
2 PRESS RELEASE DATED SEPTEMBER 26, 2024 ea021582201ex99-1_inmune.htm EX-99.1 11511
3 GRAPHIC ex99-1.jpg GRAPHIC 4668
  Complete submission text file 0001213900-24-082225.txt   222762

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20240926.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20240926_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20240926_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0215822-8k_inmune_htm.xml XML 3793
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241328777
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)